SEC and FDA Sign Information-Sharing MOU

The US Securities and Exchange Commission (SEC) and the US Food and Drug Administration (FDA) recently signed a joint memorandum of understanding (MOU). This information is according to Morgan Lewis. This agreement establishes a formal framework for sharing information between the two federal agencies.

The details

This MOU establishes protocols for information exchange between the SEC and FDA. The primary objective is to enhance regulatory oversight, particularly in areas where both agencies possess jurisdiction. These areas include the pharmaceutical and biotech sectors. The specific mechanisms for data sharing are detailed within the MOU itself. While the exact date of the signing is not specified in the provided information, the report on the MOU was published by Morgan Lewis on September 21, 2026.

The SEC's role in information collection involves disclosures from documents filed with the agency. Defense lawyer Justin Nichol Gular discussed this process on September 22, 2026, highlighting the SEC's engagement with company registration directors regarding such information. The MOU signifies a formalization of information flow between the SEC, which focuses on financial disclosures and investor protection, and the FDA, which regulates the safety and efficacy of drugs and medical devices. This collaboration is intended to allow each agency to leverage the other's data and expertise, potentially identifying issues that might otherwise go unnoticed. For instance, the FDA might share data related to clinical trial outcomes or adverse event reports that could have material financial implications for a company, which the SEC would then review for disclosure adequacy. Conversely, the SEC might flag financial irregularities or unusual trading patterns in a pharmaceutical company that could prompt an FDA investigation into product quality or regulatory compliance. This inter-agency communication aims to create a more comprehensive regulatory picture for companies operating in these complex, highly regulated industries.

Why it matters

This MOU has significant implications for companies operating in the pharmaceutical and biotech industries. It suggests increased coordination between the SEC and FDA, which could lead to more integrated regulatory scrutiny. Companies may face heightened expectations regarding the transparency and accuracy of disclosures related to drug development, clinical trial results, regulatory approvals, and financial performance. The agreement could lead to more consistent and potentially more frequent enforcement actions, as information sharing may enable both agencies to detect non-compliance more efficiently.

One second-order effect could be a shift in how companies communicate with investors about regulatory milestones, such as drug approvals, clinical trial progress, or potential regulatory setbacks. For example, if the FDA shares information with the SEC about a delayed drug approval or a significant safety concern, the SEC might scrutinize the company's public disclosures more closely to ensure investors are adequately informed. This could necessitate more proactive and detailed disclosure practices from companies to mitigate regulatory risks and maintain investor confidence.

The impact of regulatory scrutiny on company operations and disclosures is exemplified by other market events. For instance, Lufax (NYSE: LU) stock was frozen in Hong Kong after reviews of RMB3.84 billion in loan dealings. These probes into DeCheng loans and off-book deals led Lufax to restate its 2022–23 financial accounts, issue audited 2024 accounts, and tighten internal controls. This situation demonstrates how intense regulatory review can force significant operational and financial adjustments, and this MOU could create similar pressures for pharmaceutical and biotech firms regarding their specific regulatory and financial disclosures. The agreement's impact on market dynamics is unconfirmed, but it may influence investor confidence in regulated industries by signaling a more unified regulatory front. Companies like PACS Group, which announced a Chief Legal Officer transition with Patrick J. Murphy succeeding John Mitchell, may find their legal departments increasingly focused on navigating this evolving inter-agency landscape.

What to watch

Companies in the pharmaceutical and biotech sectors should monitor future guidance and pronouncements from both the SEC and the FDA. Specific disclosures or enforcement actions directly attributable to this MOU are unconfirmed, but their emergence would signal the agreement's practical implementation. The full impact of the MOU will become clearer as it is implemented and as specific cases or enforcement actions arise that demonstrate the agencies' coordinated efforts.

Companies should review their internal information-sharing protocols and disclosure practices to ensure they align with potentially increased scrutiny. This includes evaluating how information from clinical trials, regulatory submissions, and manufacturing processes is communicated internally and then translated into financial disclosures. The potential for cross-agency investigations means that a regulatory issue with the FDA could quickly become a financial disclosure issue with the SEC, and vice versa.

While not directly related to the SEC-FDA MOU, broader regulatory trends indicate a heightened focus on corporate conduct and market integrity. For example, antitrust regulators are actively scrutinizing mergers. The EU antitrust regulators are reportedly set to block the proposed €1.42 billion UPM-Sappi merger. Similarly, former FTC Chair Lina Khan warned against settling the states' antitrust suit over Paramount Skydance's $110 billion Warner Bros. Discovery deal, calling a settlement an 'illegal' merger. This occurred even as Paramount Skydance (PSKY) was reportedly in advanced talks with California officials to settle the antitrust lawsuit, leading to PSKY and WBD stocks soaring after-hours. These examples illustrate a global regulatory environment where inter-agency cooperation and rigorous oversight are increasingly common, suggesting the SEC-FDA MOU is part of a broader trend towards more comprehensive regulatory enforcement.